Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Akero Therapeutics, Inc. (NASDAQ:AKRO) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $46.83.

AKRO has been the topic of a number of research analyst reports. Citigroup began coverage on Akero Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $65.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Akero Therapeutics in a research report on Monday, November 18th.

Insider Transactions at Akero Therapeutics

In other news, VP Patrick Lamy sold 925 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total value of $28,480.75. Following the transaction, the vice president now owns 17,858 shares in the company, valued at approximately $549,847.82. This trade represents a 4.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jonathan Young sold 10,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $28.18, for a total transaction of $281,800.00. Following the sale, the chief operating officer now owns 226,286 shares of the company’s stock, valued at $6,376,739.48. This represents a 4.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 396,802 shares of company stock worth $12,396,400. Company insiders own 7.94% of the company’s stock.

Institutional Trading of Akero Therapeutics

A number of institutional investors have recently modified their holdings of the company. Simplify Asset Management Inc. lifted its holdings in Akero Therapeutics by 15.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 283,766 shares of the company’s stock worth $8,141,000 after buying an additional 38,279 shares during the period. Perceptive Advisors LLC raised its holdings in shares of Akero Therapeutics by 8.1% during the second quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock valued at $35,188,000 after acquiring an additional 112,426 shares in the last quarter. FMR LLC lifted its stake in Akero Therapeutics by 732.1% in the third quarter. FMR LLC now owns 30,337 shares of the company’s stock worth $870,000 after acquiring an additional 26,691 shares during the period. Bank of New York Mellon Corp boosted its holdings in Akero Therapeutics by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 251,234 shares of the company’s stock valued at $5,894,000 after acquiring an additional 61,988 shares in the last quarter. Finally, Propel Bio Management LLC increased its position in Akero Therapeutics by 4.9% during the 3rd quarter. Propel Bio Management LLC now owns 343,729 shares of the company’s stock valued at $9,862,000 after purchasing an additional 15,977 shares during the period.

Akero Therapeutics Stock Up 0.7 %

Shares of NASDAQ AKRO opened at $28.56 on Thursday. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average of $30.83 and a 200-day moving average of $27.63. The firm has a market capitalization of $1.99 billion, a price-to-earnings ratio of -7.62 and a beta of -0.23. Akero Therapeutics has a 12 month low of $15.32 and a 12 month high of $37.00.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). Sell-side analysts expect that Akero Therapeutics will post -3.96 earnings per share for the current fiscal year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.